192 related articles for article (PubMed ID: 25274076)
1. Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease.
Mazzucchi S; Frosini D; Ripoli A; Nicoletti V; Linsalata G; Bonuccelli U; Ceravolo R
Acta Neurol Scand; 2015 Mar; 131(3):191-5. PubMed ID: 25274076
[TBL] [Abstract][Full Text] [Related]
2. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
[TBL] [Abstract][Full Text] [Related]
3. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
[TBL] [Abstract][Full Text] [Related]
4. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
6. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
7. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Fidalgo C; Ko WK; Tronci E; Li Q; Stancampiano R; Chuan Q; Bezard E; Carta M
Neuroscience; 2015 Jul; 298():389-96. PubMed ID: 25907446
[TBL] [Abstract][Full Text] [Related]
8. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
Politis M; Wu K; Loane C; Brooks DJ; Kiferle L; Turkheimer FE; Bain P; Molloy S; Piccini P
J Clin Invest; 2014 Mar; 124(3):1340-9. PubMed ID: 24531549
[TBL] [Abstract][Full Text] [Related]
9. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Bishop C; George JA; Buchta W; Goldenberg AA; Mohamed M; Dickinson SO; Eissa S; Eskow Jaunarajs KL
Eur J Neurosci; 2012 Sep; 36(6):2839-48. PubMed ID: 22762478
[TBL] [Abstract][Full Text] [Related]
10. Motor complications in an incident Parkinson's disease cohort.
Scott NW; Macleod AD; Counsell CE
Eur J Neurol; 2016 Feb; 23(2):304-12. PubMed ID: 26074125
[TBL] [Abstract][Full Text] [Related]
11. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.
Cilia R; Akpalu A; Sarfo FS; Cham M; Amboni M; Cereda E; Fabbri M; Adjei P; Akassi J; Bonetti A; Pezzoli G
Brain; 2014 Oct; 137(Pt 10):2731-42. PubMed ID: 25034897
[TBL] [Abstract][Full Text] [Related]
12. Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients.
Arbouw ME; Movig KL; Neef C; Guchelaar HJ; Egberts TC
Eur J Clin Pharmacol; 2007 Feb; 63(2):181-7. PubMed ID: 17200834
[TBL] [Abstract][Full Text] [Related]
13. Current treatment and future prospects of dopa-induced dyskinesias.
Mazzucchi S; Frosini D; Bonuccelli U; Ceravolo R
Drugs Today (Barc); 2015 May; 51(5):315-29. PubMed ID: 26097904
[TBL] [Abstract][Full Text] [Related]
14. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
15. [Dyskinesia caused by L-DOPA].
Derkinderen P; Vidailhet M
Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
[TBL] [Abstract][Full Text] [Related]
16. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
[TBL] [Abstract][Full Text] [Related]
17. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study.
Katzenschlager R; Manson AJ; Evans A; Watt H; Lees AJ
J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):295-7. PubMed ID: 14742609
[TBL] [Abstract][Full Text] [Related]
18. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
[TBL] [Abstract][Full Text] [Related]
19. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
20. Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.
Timpka J; Fox T; Fox K; Honig H; Odin P; Martinez-Martin P; Antonini A; Chaudhuri KR
Acta Neurol Scand; 2016 Jun; 133(6):451-8. PubMed ID: 26358227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
